Objectives: The objective was to compare specific data from the 2020 National Confidential Enquiry into Patient Outcome and Death (NCEPOD) report "Balancing the Pressures" with two previous U.K. studies and to examine changes in the pediatric population requiring long-term ventilation (LTV) as well as the types delivered. We believe that the new data presented will facilitate future service planning.

Design: A subset of confidential enquiry data derived from a study by a nationally funded quality improvement organization (NCEPOD: www.ncepod.org.uk ) was compared with two previous U.K. datasets.

Setting: Healthcare providers across England, Wales, and Northern Ireland-inpatient and community settings.

Patients: Children and young people (CAYP) 0-16 years old receiving LTV between April 1, 2016, and March 31, 2018.

Interventions: None.

Measurements And Main Results: When comparing the NCEPOD data with that last published in the United Kingdom, the number of CAYP requiring LTV more than doubled between 2008 and 2018 (933-2,093). There has also been a particular increase in the proportion of children that were under two when they were commenced on LTV (26-39.2%). Children are now more likely than previously to be receiving LTV to manage upper airway obstruction and CNS conditions. There has also been an approximate doubling of those receiving LTV over the whole 24-hour period (9.4-18.4%).

Conclusions: The increased numbers and changing characteristics of babies and children requiring LTV over the last 3 decades in the United Kingdom have implications for all healthcare sectors but particularly for providers of critical care services.

Download full-text PDF

Source
http://dx.doi.org/10.1097/PCC.0000000000003253DOI Listing

Publication Analysis

Top Keywords

receiving ltv
12
long-term ventilation
8
children young
8
critical care
8
care services
8
confidential enquiry
8
united kingdom
8
requiring ltv
8
ltv
7
children
5

Similar Publications

Letermovir for Prevention of Recurrent Cytomegalovirus in High-Risk Allogeneic Hematopoietic Cell Transplantation Recipients.

Transplant Cell Ther

December 2024

Infectious Diseases Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address:

We evaluated letermovir (LTV) for secondary prophylaxis for cytomegalovirus (CMV) in allogeneic hematopoietic cell transplant recipients (HCT) at high-risk for CMV recurrence. This open-label study was conducted at Memorial Sloan Kettering Cancer Center and the University of Minnesota. Patients with clinically significant CMV infection (cs-CMVi) and ≥1 high-risk criteria for CMV who achieved viral suppression with standard CMV antivirals received LTV secondary prophylaxis for up to 14 weeks.

View Article and Find Full Text PDF
Article Synopsis
  • Cord blood transplantation (CBT) has a high risk of cytomegalovirus (CMV) infection, and Letermovir (LTV) is an effective drug for preventing CMV reactivation after CBT.
  • A study involving 79 adult patients revealed that those who received LTV had significantly lower rates of CMV reactivation compared to those who did not, with 11.1% versus 82.4% at day 100 and 45.3% versus 82.4% at one year.
  • Despite the lower reactivation rates, approximately 34.2% of patients experienced late CMV reactivation after stopping LTV, suggesting the need for ongoing monitoring and potential extension of LTV use
View Article and Find Full Text PDF

Background: Cytomegalovirus (CMV) is associated with detrimental outcomes after lung transplantation (LTX); primary prophylaxis (PPX) with valganciclovir (VGC) is guideline-recommended. VGC is associated with myelosuppression, spurring interest in letermovir (LTV).

Methods: Adults undergoing LTX between January 1, 2021, and July 30, 2022 at our institution who were converted from VGC to LTV for PPX were evaluated.

View Article and Find Full Text PDF
Article Synopsis
  • Letermovir (LTV) prophylaxis significantly reduces the incidence of clinically significant cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  • A study of 230 patients показал that those receiving LTV experienced a higher rate of Epstein-Barr virus (EBV) reactivation (27%) compared to those who did not receive LTV (13%).
  • Despite the increased EBV reactivation, there were no major differences in recovery metrics, overall survival, or other complications between the LTV and control groups, suggesting a possible link between LTV use and increased EBV reactivation post-transplant.
View Article and Find Full Text PDF

Physiologic Comparison of Airway Pressure Release Ventilation and Low Tidal Volume Ventilation in ARDS: A Randomized Controlled Trial.

Chest

September 2024

School of Biomedical Engineering, Guangzhou Medical University, Guangzhou, Guangdong, China; Institute of Technical Medicine, Furtwangen University, Villingen-Schwenningen, Germany.

Background: The physiologic effects of different ventilation strategies on patients with ARDS need to be better understood.

Research Question: In patients with ARDS receiving controlled mandatory ventilation, does airway pressure release ventilation (APRV) improve lung ventilation/perfusion (V˙/Q˙) matching and ventilation homogeneity compared with low tidal volume (LTV) ventilation?

Study Design And Methods: This study was a single-center randomized controlled trial. Patients with moderate to severe ARDS were ventilated randomly with APRV or LTV ventilation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!